Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Amino acid PET tracer tells brain metastases from radiation injury

Delayed brain injury resulting from aggressive radiation treatment can be differentiated from recurrent brain tumors using F-18 FDOPA PET imaging, according to a study published Oct. 28 in the Journal of Nuclear Medicine.

Several new genes found related to Alzheimer's

New research brings 11 new genes into focus as potential links to Alzheimer's and other neurodegenerative diseases including Parkinson's and multiple sclerosis, all associated with the build-up of protein plaques in the brain. The data was made available as a result of the international Genomics of Alzheimer's Project (IGAP), according to an Oct. 28 report by The Huffington Post.

Worldwide PET market expected to grow modestly

The global PET market is set to grow an estimated 3.74 percent from 2012-2016, according to a report published this month by the market research firm Infiniti Research Limited.

Mixed results from phase III flurpiridaz PET trial

Lantheus Medical Imaging has announced preliminary phase III clinical trial results for F-18 flurpiridaz as a diagnostic PET agent for myocardial perfusion imaging indicating high sensitivity but potentially lagging specificity for the detection of CAD.

Regadenoson on FDA watch for adverse effects

The FDA has added regadenoson, an adenosine myocardial perfusion agent used during cardiac stress tests, to its most recent watch list for potentially life-threatening side effects.

PET: A better tactic for imaging head trauma

Imaging the inflammatory response with PET could provide more information about traumatic brain injury (TBI) than conventional CT and MRI methods, according to research presented during the Military Health System Research Symposium held in Ft. Lauderdale, Fla., Aug. 12.

Early PET/CT superior to RECIST for tipping off long-term outcomes

Undergoing a pretreatment PET/CT scan has shown to have more predictive value than conventional follow-up protocol for colorectal cancer with metastases to the liver and could be the case for other cancers, according to a study published Oct. 17 in the Journal of Nuclear Medicine.

Vizamyl approved by FDA to aid dementia diagnosis

The FDA today cleared a new PET amyloid imaging agent—F-18 flutemetamol (Vizamyl). The addition of Vizamyl provides more options for dementia experts evaluating amyloid in the brain to rule out Alzheimer’s and other neurodegenerative disease.